Humanised antibodies against pathogenic fungi
AssigneeDiatheva S.R.L.
InventorsTomas DI MAMBRO, Tania VANZOLINI, Mauro MAGNANI
Life of this patent
Estimating the term…
Abstract
The present invention relates to humanised antibody molecules having specificity for β-1,3 glucans and compositions comprising the same. The present invention also relates to the therapeutic uses of the antibody molecules, wherein said use is in the treatment or prophylaxis of fungal infections. It is further claimed a synergistic combination of a) at least one humanised antibody which has specificity for β-1,3 glucans and b) one or more antifungal agents for use in the treatment or prophylaxis of infections of human cells.
Claims17
A humanised antibody which has specificity for (β-1,3 glucans of pathogenic fungi, or fragments or fusion proteins thereof, comprising:
- (i) a CDRH1 having at least 90% of identity with the sequence SYWLE (SEQ ID NO:
- 10.
- (ii) a CDRH2 having at least 90% of identity with the sequence
- (SEQ ID NO:
- 12)
- EILPGSGSTNYNEKFKG
- (iii) a CDRH3 having at least 90% of identity with the sequence EGWYFDV (SEQ ID NO:
- 14)
- (iv) a CDRL1 having at least 90% of identity with the sequence QSLLYSNGNTH (SEQ ID NO:
- 9)
- (v) a CDRL2 having at least 90% of identity with the sequence LVS (SEQ ID NO:
- 11), and
- (vi) a CDRL3 having at least 90% of identity with the sequence VQGTHFPYT (SEQ ID NO:
- 13).
A combination of a) at least one humanised antibody which has specificity for β-1,3 glucans and b) one or more antifungal agents for use in the treatment or prophylaxis of infections of human cells.
A pharmaceutical composition comprising a) at least one humanised antibody which has specificity for β-1,3 glucans and b) one or more antifungal agents with one or more of a pharmaceutically acceptable excipient, diluent or carrier.
Dependencies are inferred from the claim text.